Scarica l'app Stockscreener
4.10
4.33%
0.17
Dopo l'orario di chiusura:
4.05
-0.05
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.93
Aprire:
$3.95
Volume 24 ore:
2.15M
Relative Volume:
0.88
Capitalizzazione di mercato:
$1.25B
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
82.00
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+3.54%
1M Prestazione:
+8.04%
6M Prestazione:
-31.09%
1 anno Prestazione:
-30.39%
Intervallo 1D:
$3.95
$4.13
Intervallo di 1 settimana:
$3.7378
$4.13
Portata 52W:
$3.51
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Confronta MNKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.10 | 1.19B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind stock price target lowered to $8 at RBC Capital on model updates - Investing.com
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association - Insider Monkey
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
What analysts say about MannKind Corporation stockLightning-fast capital gains - jammulinksnews.com
What drives MannKind Corporation stock priceExtraordinary profit generation - Autocar Professional
MannKind Corporation Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
MannKind (NASDAQ:MNKD) Upgraded at HC Wainwright - Defense World
Mannkind director Binder sells $296945 in shares By Investing.com - Investing.com India
H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com
What makes MannKind Corporation stock price move sharplyLow Risk Scalping Alerts - Newser
How MannKind Corporation stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser
High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance
Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Insider Monkey
13 Best Healthcare Stocks to Buy Under $10 - Insider Monkey
Wedbush Remains Bullish on MannKind Corporation (MNKD) - Insider Monkey
13 Stocks Under $5 With High Upside Potential - Insider Monkey
MannKind Corp stock hits 52-week low at $3.63 - Investing.com
MannKind Corporation(NasdaqGM: MNKD) dropped from Russell 3000 Value Index - MarketScreener
Today In SCV History: June 27, 2014 – Valencia Company Given FDA Approval For Inhaled Insulin - KHTS Radio
Is Day One Biopharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Insider Monkey
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
MannKind stock hits 52-week low at $3.70 - Investing.com
Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga
Top 3 Oversold Healthcare Stocks to Watch for Rocket-Like Growth - AInvest
Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus
MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa
MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia
Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech
MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria
MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada
MannKind to present inhaled insulin study at ADA event - Investing.com
Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia
MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
Mannkind Corp (MNKD) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):